Gastrointestinal Cancer Committee

Purpose
The purpose of the NRG Gastrointestinal (GI) Cancer Committee is to reduce the burden of GI malignancies in patients. The GI Cancer Committee focuses on testing new hypothesis through clinical trials aimed to improve patient outcomes with GI malignancies. Additionally, the committee focuses on establishing new standard of care that can be applied to all patients.

The goals of this committee include establishing innovative clinical care through evidence-based clinical trials, engaging patients and caregivers in trials and trial development, supporting career development of early career investigators, educating oncology providers on new technologies and techniques, and facilitating team science and multidisciplinary care. This group meets at the NRG Semiannual Meetings, monthly or bi-monthly within Working Groups, and ad-hoc as necessary.

Gastrointestinal Cancer Committee Leadership

Colorectal Chair

Thomas George, MD

Colorectal Vice Chair

Scott Kopetz, MD, PhD, FACP

Non-Colorectal Chair

Theodore Hong, MD

Non-colorectal Vice Chair

David Ilson, MD, PhD

Working Groups

Pancreas GI Subsite Working Group

Chair

Nina Sanford

Hepatobiliary GI Subsite Working Group

Chair

Laura Dawson

Esophagogastric GI Subsite Working Group

Chair

David Ilson

Neuroendocrine Tumor Working Group

Chair

Heloisa Soares

Anal GI Subsite Working Group

Chair

Jennifer Dorth

Colon GI Subsite Working Group

Chair

Christina Wu

Rectal GI Subsite Working Group

Chair

Kathryn Hitchcock

Committee Members
Colorectal Cancer Core Committee
  • Gerard Abood
  • Ross Abrams
  • Olatunji Alese
  • Ghassan Abou-Alfa
  • Manik Amin
  • Christopher Anker
  • Michael Bassetti
  • Rimini Breakstone
  • Gary Buchshacher
  • Michael Buckstein
  • Cameron M. Callaghan
  • Jason Cheng
  • Steven Cohen
  • Madison L. Conces
  • Christopher Crane
  • Michael Cusnir
  • Prajnan Das
  • Arvind Dasari
  • Gemma Davies
  • Laura Dawson
  • Asha Dhanarajan
  • Maria Diab
  • Jennifer Dorth
  • Kevin Du
  • Jesus Fabregas
  • Marwan Fakih
  • Vaia Florou
  • Erin Fukaya
  • Thomas George
  • Jun Gong
  • Karyn Goodman
  • Michael Haddock
  • William Hall
  • Christopher Hallemeier
  • Kathryn Hitchcock
  • Theodore Hong
  • David Horowitz
  • David Ilson
  • Atif Iqbal
  • Alison Ivey
  • Salma Jabbour
  • Einsley-Marie Janowski
  • Krishnan Jethwa
  • Andrea Johnston
  • Lisa Kachnic
  • Yesenia Rojas-Khalil
  • Jordan Kharofa
  • Aoife Kilcoyne
  • George P. Kim
  • Hyun Kim
  • Samuel Klempner
  • Tatjana Kolevska
  • Scott Kopetz
  • Geoffrey Ku
  • James Lee
  • Sangjune Lee
  • Caio Rocha Lima
  • Jolinta Lin
  • Yan Lin
  • Diane C. Ling
  • Kimberly Mak
  • Harvey Mamon
  • Khalid Matin
  • Malcolm Mattes
  • Eric Miller
  • Timur Mitin
  • Juan Pablo Moreno
  • Van Morris
  • Qadan Motaz
  • Neil Newman
  • Romaine Charles Nichols
  • Manisha Palta
  • Parag Parikh
  • William Parker
  • Pretesh Patel
  • Brian Ramnaraign
  • Marsha Reyngold
  • Hannah J Roberts
  • Sherise Rogers
  • Paul Romesser
  • Marcia Russell
  • Howard Safran
  • Mohamed Salem
  • Joel Saltzman
  • Nina Sanford
  • Steven Seyedin
  • Walid Shaib
  • Timothy Showalter
  • Zain Siddiqui
  • Heloisa Soares
  • Tarita Thomas
  • Richard Tuli
  • Noam VanderWalde
  • Raymond C Wadlow
  • Terrence Williams
  • Jennifer Wo
  • Christina Wu
  • Evan Wuthrick
  • Greg Yothers
  • Janie Y Zhang
Non-Colorectal Cancer Core Committee
  • Matthew Abrams
  • Ross Abrams
  • Olatunji Alese
  • Christopher Anker
  • Mekhail Anwar
  • Michael Bassetti
  • Bruno Bockorny
  • Gehan Botrus
  • Rimini Breakstone
  • Michael Chuong
  • Steven Cohen
  • Christopher Crane
  • Prajnan Das
  • Arvind Dasari
  • Gemma Davies
  • Laura Dawson
  • Asha Dhanarajan
  • Maria Diab
  • Jennifer Dorth
  • Mary Feng
  • Erin Fukaya
  • Thomas George
  • Jun Gong
  • Karyn Goodman
  • Chandan Guha
  • Michael Haddock
  • William Hall
  • Christopher Hallemeier
  • Lauren Elizabeth Henke
  • Joseph Herman
  • Kathryn Hitchcock
  • Theodore Hong
  • David P Horowitz
  • Jasmine Huynh
  • David Ilson
  • Atif Iqbal
  • Salma Jabbour
  • Einsley-Marie Janowski
  • Krishnan Jethwa
  • Andrea Johnston
  • Lisa Kachnic
  • Jordan Kharofa
  • Aoife Kilcoyne
  • George P. Kim
  • Hyun Kim
  • Emily Kinssey
  • Samuel Klempner
  • Eugene Koay
  • Sunil Krishnan
  • Geoffrey Ku
  • Sangjune Lee
  • Caio Rocha Lima
  • Jolinta Lin
  • Amit Mahipal
  • Kimberly Mak
  • Harvey Mamon
  • Khalid Matin
  • Eric Miller
  • Timur Mitin
  • Qadan Motaz
  • Ibrahim Nassour
  • Neil Newman
  • Romaine Charles Nichols
  • Ryan Nipp
  • Russell Palm
  • Manisha Palta
  • Parag Parikh
  • William Parker
  • Pretesh Patel
  • Brian Ramnaraign
  • Avani Rao
  • Marsha Reyngold
  • Hannah J Roberts
  • Sherise Rogers
  • Paul Romesser
  • Howard Safran
  • Ilyas Sahin
  • Mohamed Salem
  • Joel Saltzman
  • Nina Sanford
  • Steven Seyedin
  • Walid Shaib
  • Timothy Showalter
  • Farzan Siddiqui
  • Austin J. Sim
  • Heloisa Soares
  • Leila Tchelebi
  • Tarita Thomas
  • Richard Tuli
  • Noam VanderWalde
  • Raymond C Wadlow
  • Terence Williams
  • Kathryn Winter
  • Jennifer Wo
  • Christina Wu
  • Evan Wuthrick
  • Zhen Zhang
    >>>>>>>>>>>>
    Study Title Status Phase Disease Category Disease Site
    NRG-GI008Colon Adjuvant Chemotherapy based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)Open to AccrualII/IIIGastrointestinal [GI]Colorectal
    NRG-GI007Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who are Not Candidates for SurgeryClosed to AccrualIGastrointestinal [GI]Esophageal
    NRG-GI005Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA
    Colon Cancer (COBRA)
    Closed to AccrualII/IIIGastrointestinal [GI]Colorectal
    RTOG-1112Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular CarcinomaClosed to AccrualIIIGastrointestinal [GI]Liver
    NRG-GI006Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal CancerOpen to AccrualIIIGastrointestinal [GI]Esophageal
    NRG-GI003A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular CarcinomaOpen to AccrualIIIGastrointestinal [GI]Liver
    NRG-GI002A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal CancerClosed to AccrualIIGastrointestinal [GI]Anal Canal
    NRG-GI001Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic CholangiocarcinomaTerminatedIIIGastrointestinal [GI]Liver
    RTOG-0848A Phase IIR and a Phase III Trial Evaluating Both Erlotinib (Ph IIR) And Chemoradiation (Ph III) As Adjuvant Treatment For Patients With Resected Head Of Pancreas AdenocarcinomaClosed to AccrualII/IIIGastrointestinal [GI]Pancreas
    RTOG-0436A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without SurgeryTerminatedIIIGastrointestinal [GI]Esophageal
    RTOG-1010A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal AdenocarcinomaTerminatedIIIGastrointestinal [GI]Esophageal
    NRG-GI004/SWOG-S1610Colorectal Cancer Metastatic dMMR/MSI-H Immuno-therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-high (MSI-H) Metastatic Colorectal CancerOpen to AccrualIIIGastrointestinal [GI]Colorectal

    Stay current with science. Sign up for our newsletter.

    Support NRG Oncology.
    Help Our Cause.

    We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

    Donate Today

    NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.